bioAffinity Technologies announces virtual physician roundtable on CyPath® Lung for April 8, 2026

bioAffinity Technologies, Inc.

Webinar titled 'CyPath® Lung in Practice: A Physician Roundtable Discussion' on April 8, 2026 at 7 p.m. ET.
Moderated by CMO Gordon H. Downie, MD, PhD; panel includes three pulmonologists sharing real-world cases.
CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with small nodules.
First of a series aimed at integrating noninvasive CyPath® Lung into pulmonary practice for nodule management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.